Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.
Marina Kremyanskaya, MD, PhD, assistant professor of medicine, hematology, and medical oncology at Mount Sinai Hospital, discusses unmet needs in myelofibrosis.
Myelofibrosis is a rare disease and there is not as much awareness about this malignancy, according to Kremyanskaya. When patients are diagnosed with myelofibrosis, they can have physically and emotionally adverse events. There are few treatment options available to them currently, according to Kremyanskaya.
There is a huge unmet need for new therapies in the second- or third-line setting for these patients after they fail approved therapies, or for specific patient populations, such as patients who experience anemia, says Kremyanskaya. These patients need therapies that target different mechanisms of action and work differently, concludes Kremyanskaya.